

ASX Announcement and Media Release

Date: 28 January 2003

DOMANTIS APPOINTS SENIOR DIRECTOR, THERAPEUTIC TARGETS

Domantis Limited, the company in which Peptech will hold a 36.1% interest, made the following announcement yesterday in relation to a new senior executive appointment.

“Domantis Appoints Dr Steve Holmes, formerly of Oxford GlycoSciences and GSK, as Senior Director, Therapeutic Targets

Cambridge, UK and USA, 27 January, 2003... Domantis Limited, the leading Domain Antibody (dAb) drug discovery company, has appointed Dr Steve Holmes, formerly Director of Antibody Discovery at Oxford GlycoSciences plc, as Senior Director, Therapeutic Targets.

Dr Holmes, has over 18 years experience in the international pharmaceutical industry. He spent the last two years at Oxford GlycoSciences, where he was responsible for developing the therapeutic antibody programmes, directing antibody research and managing pre-clinical studies through to IND filings. He also managed a number of scientific alliances during his time with the company.

Prior to Oxford GlycoSciences, Dr Holmes was head of High Throughput Biology, Europe at GlaxoSmithKline (GSK), which he joined from SmithKline Beecham (SKB) following the merger. Dr Holmes joined SKB in 1989 and held a number of senior scientific management posts at the company including those involving the generation and production of therapeutic antibodies and culminating in his appointment as Head of Antibody Technologies and Immunology in 1997. During his career with SKB he led numerous research initiatives involving recombinant antibodies/proteins for therapy in oncology, asthma and inflammation. At the time of the merger he was UK Head of Large Scale Mammalian and Bacterial Recombinant Protein Production.

Domantis CEO Robert Connelly said, ‘We are delighted to welcome a scientist of Steve’s calibre and track record to the company. He has directly relevant experience in selecting drug targets, managing successful therapeutic programmes, progressing antibody programmes from inception to market and leading collaborative ventures.

He will prove an invaluable asset to Domantis and joins the company at a pivotal time when we are expanding our portfolio of dAb therapeutic leads, securing a series of technology license and collaboration agreements and rapidly progressing our dAbs into pre-clinical studies.’

Dr Holmes gained his BSc in organic chemistry/physiology and PhD in thyroid autoimmune disease at the University of Sheffield and undertook postdoctoral research studies at Baylor College of Medicine, Houston, Texas, US. At Baylor he progressed to Assistant Professor and obtained several National Institute of Health funded research grants in the field of Sertoli cell function. Dr Holmes is author of over 50 scientific publications and named inventor on numerous patents. His first commercial position was as Manager of Immunology at Flemming GmbH”.

Managing Director Stephen Kwik said “The fact that Domantis has attracted a person with the experience and seniority of Dr Holmes augers well for its future”.

For further information please contact:

STEPHEN KWIK
MANAGING DIRECTOR
PEPTECH LIMITED
Ph (02) 9870 8788

Dr PAUL SCHOBBER
INVESTOR RELATIONS
PEPTECH LIMITED
Ph (02) 9870 8788